Merit Medical Systems, Inc. Aktie News

Fred Lampropoulos will continue to serve as Chairman of Merit's Board of Directors Merit announces preliminary unaudited revenue for the quarter ended June 30, 2025 SOUTH JORDAN, Utah, July 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today the appointment of Martha Aronson as Merit's new President and Chief Executi...

SOUTH JORDAN, Utah, July 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2025, after the close of the stock market on Wednesday, July 30, 2025. Merit plans to hold its investor conference call on the same day (Wed...

Stocks that aren't sensitive to economic ups and downs are a smart way to protect your portfolio.

SOUTH JORDAN, Utah, May 20, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that it has acquired Biolife Delaware, L.L.C. (“Biolife”) in a merger transaction through which Biolife has become a wholly-owned subsidiary of Merit. Biolife, which is headquartered in Sarasota, Florida, manufactures unique patented hemostat...

SOUTH JORDAN, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the Wrapsody Cell-Impermeable Endoprosthesis (CIE) received regulatory approval from Health Canada. With this approval, Merit intends to begin immediate commercialization of the device throughout Canada with devices shipped from Merit's ...

In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months. In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months.

Merit Medical Systems, Inc. (NASDAQ:MMSI ) Q1 2025 Results Conference Call April 24, 2025 5:00 PM ET Company Participants Fred Lampropoulos - Founder, Chairman & Chief Executive Officer Raul Parra - Chief Financial Officer and Treasurer Brian Lloyd - Chief Legal Officer & Corporate Secretary Conference Call Participants Jason Bednar - Piper Sandler Steve Lichtman - Oppenheimer Robbie Marcus - J...

Novel all-in-one retrograde aortic access delivery system supports streamlined treatment of ventricular tachycardia Novel all-in-one retrograde aortic access delivery system supports streamlined treatment of ventricular tachycardia